We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal
Read MoreHide Full Article
Shares of Galera Therapeutics, Inc. (GRTX - Free Report) were down almost 70% on Tuesday after the company announced unsatisfactory data from the phase III ROMAN study evaluating avasopasem for treating severe oral mucositis (“SOM”) in patients with locally advanced head and neck cancer (“HNC”) who are undergoing standard-of-care radiotherapy.
The study failed to meet the endpoint of reduction in the incidence of SOM. Data from the study showed 16% relative reduction in the incidence of SOM in the avasopasem treatment group (54%) as compared to the placebo group (64%).
Per the company, though the study demonstrated reductions in the incidence, duration and severity of SOM, it did not achieve statistical significance for the primary endpoint.
Galera’s stock has plunged 78% so far this year compared with the industry’s decrease of 11.8%.
Image Source: Zacks Investment Research
We note that oral mucositis is a side effect of radiation therapy. The double-blind, placebo-controlled ROMAN study was evaluating avasopasem in patients with locally advanced HNC who are receiving seven weeks of standard-of-care radiotherapy plus cisplatin. The company continues to analyze the above-mentioned data.
Galera is also evaluating avasopasem in the phase IIa AESOP study for the reduction of radiation-induced esophagitis in patients with lung cancer. Top-line data from this study is expected in the first half of 2022.
This apart, the company is developing another product candidate, GC4711, in early- to mid-stage studies, to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
We note that Galera has no approved product in its portfolio at the moment. Therefore, the successful development of avasopasem and other pipeline candidates remains critical for the company’s growth.
Fulcrum Therapeutics’ loss per share estimates have narrowed 2.2% for 2021 and 2.5% for 2022, over the past 60 days. The stock has soared 102.4% year to date.
Athenex’s loss per share estimates have narrowed 9% for 2021 and 9.2% for 2022, over the past 60 days.
Amicus Therapeutics’ loss per share estimates have narrowed 1.3% for 2021 and 37.5% for 2022, over the past 60 days.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal
Shares of Galera Therapeutics, Inc. (GRTX - Free Report) were down almost 70% on Tuesday after the company announced unsatisfactory data from the phase III ROMAN study evaluating avasopasem for treating severe oral mucositis (“SOM”) in patients with locally advanced head and neck cancer (“HNC”) who are undergoing standard-of-care radiotherapy.
The study failed to meet the endpoint of reduction in the incidence of SOM. Data from the study showed 16% relative reduction in the incidence of SOM in the avasopasem treatment group (54%) as compared to the placebo group (64%).
Per the company, though the study demonstrated reductions in the incidence, duration and severity of SOM, it did not achieve statistical significance for the primary endpoint.
Galera’s stock has plunged 78% so far this year compared with the industry’s decrease of 11.8%.
We note that oral mucositis is a side effect of radiation therapy. The double-blind, placebo-controlled ROMAN study was evaluating avasopasem in patients with locally advanced HNC who are receiving seven weeks of standard-of-care radiotherapy plus cisplatin. The company continues to analyze the above-mentioned data.
Galera is also evaluating avasopasem in the phase IIa AESOP study for the reduction of radiation-induced esophagitis in patients with lung cancer. Top-line data from this study is expected in the first half of 2022.
This apart, the company is developing another product candidate, GC4711, in early- to mid-stage studies, to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
We note that Galera has no approved product in its portfolio at the moment. Therefore, the successful development of avasopasem and other pipeline candidates remains critical for the company’s growth.
Zacks Rank & Stocks to Consider
Galera currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include Fulcrum Therapeutics, Inc. (FULC - Free Report) , Athenex, Inc. and Amicus Therapeutics, Inc. (FOLD - Free Report) , all carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Fulcrum Therapeutics’ loss per share estimates have narrowed 2.2% for 2021 and 2.5% for 2022, over the past 60 days. The stock has soared 102.4% year to date.
Athenex’s loss per share estimates have narrowed 9% for 2021 and 9.2% for 2022, over the past 60 days.
Amicus Therapeutics’ loss per share estimates have narrowed 1.3% for 2021 and 37.5% for 2022, over the past 60 days.